Innovative solutions

Disruptive strategy to elicit protective immunity against Multidrug-resistant (MDR) Gram-negative bacteria

RemAb is developing a pipeline with different indications. Our most advanced program aims to provide immediate protection to patients admitted to Intensive Care Units (ICU) without generating antimicrobial resistance (AMR).

Read more



RemAb Therapeutics is a spin‐off of Bellvitge Biomedical Research Institute (IDIBELL), based in Barcelona.

Read more


Antimicrobial resistance (AMR) is a growing global threat to human health and economic development.

Read more


RA-01 is novel drug product and a first line therapy for preventing nosocomial infections at ICUs.

Read more



Grants and Awards


Grant from

IT Health

European Commission

HeadStart Program

July / 2018

Ref. 2018-HS-0010

Read more

Grant from

Caixa Capital Risk

Obra Social "La Caixa"

CaixaImpulse program

July / 2016

Ref.: CI16-00037

Read more


Grant from


Generalitat de Catalunya

Fons de Patents Gínjol Program

GAS-1: 2017 – 3rd edition

GAS: 2016 - 1st edition 

Read more


Grant from

SME phase-I

European Comission

Horizon 2020

December/ 2018

Ref.: Coming soon

Read more